ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,29355
-0,98%
Bitcoin
69.428,57
0,14%
Brent Oil
79,395
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immatics NV (IMTX)

  7. Immatics NV (IMTX) Notícias

IMTX

Immatics NV (IMTX)

Immatics NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMTX
DataHoraFonteTítuloCódigoCompanhia
14/05/202408:00GlobeNewswire Inc.Immatics Announces First Quarter 2024 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
21/03/202408:00GlobeNewswire Inc.Immatics Announces Full Year 2023 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
22/01/202414:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
19/01/202410:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
17/01/202422:30GlobeNewswire Inc.Immatics Announces Pricing of $175 Million Public OfferingNASDAQ:IMTXImmatics NV
17/01/202418:01GlobeNewswire Inc.Immatics Announces Proposed Public OfferingNASDAQ:IMTXImmatics NV
16/01/202406:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
30/11/202306:00GlobeNewswire Inc.Levicept Appoints Eliot Forster as CEONASDAQ:IMTXImmatics NV
14/11/202309:00GlobeNewswire Inc.Immatics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
08/11/202309:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNASDAQ:IMTXImmatics NV
24/10/202308:00GlobeNewswire Inc.Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyNASDAQ:IMTXImmatics NV
14/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMTXImmatics NV
13/09/202318:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IMTXImmatics NV
11/09/202308:00GlobeNewswire Inc.Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNASDAQ:IMTXImmatics NV
25/08/202317:11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IMTXImmatics NV
17/08/202308:00GlobeNewswire Inc.Immatics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
10/08/202308:00GlobeNewswire Inc.Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsNASDAQ:IMTXImmatics NV
24/07/202308:00GlobeNewswire Inc.Immatics Announces $35 Million Equity Investment from Bristol Myers SquibbNASDAQ:IMTXImmatics NV
20/06/202317:21Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202308:00GlobeNewswire Inc.Immatics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
02/05/202308:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMENASDAQ:IMTXImmatics NV
01/05/202308:00GlobeNewswire Inc.Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic CollaborationNASDAQ:IMTXImmatics NV
22/03/202307:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:IMTXImmatics NV
21/03/202308:31GlobeNewswire Inc.Immatics Announces Full Year 2022 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
14/02/202319:24Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IMTXImmatics NV
07/02/202308:07Edgar (US Regulatory)Schedule 13g
(sc 13g)		NASDAQ:IMTXImmatics NV
21/11/202201:15TipRanksSVB Securities Sticks to Their Buy Rating for Immatics (IMTX)NASDAQ:IMTXImmatics NV
17/11/202220:15TipRanksChardan Capital Sticks to Their Buy Rating for Immatics (IMTX)NASDAQ:IMTXImmatics NV
17/11/202209:00GlobeNewswire Inc.Immatics Announces Third Quarter 2022 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
11/10/202207:31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IMTXImmatics NV
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMTX

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
SUZB3
SUZANO PAPEL ON
BOV
RPMG3
PET MANGUINH ON
BOV
SAPR4
SANEPAR PN
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
SGPS3
SPRINGS ON
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados